The European Medicines Agency has added 17 new products to its latest monthly list of medicines that are under review for potential pan-EU marketing authorization, including rozanolixizumab, aumolertinib and ustekinumab.
Rozanolixizumab is UCB’s investigational treatment for generalized myasthenia gravis (gMG). It is one of two investigational gMG treatments from...








